- Protocol Short Name and Number: TransIT, 2202
- Protocol Long Name: A Phase III Randomized Trial Comparing Unrelated Donor BMT With IST for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia
- Key Personnel
- BMT CTN # 2202 Co-Chair: David Williams, MD
- BMT CTN # 2202 Co-Chair: Michael Pulsipher, MD
- BMT CTN # 2202 Co-Chair: Bronwen Shaw, MD
- BMT CTN # 2202 Protocol Coordinator(s): Kristi Wilmes (kwilmes@nmdp.org), Leah Cheng (leah.cheng@childrens.harvard.edu)
- Additional Contacts: TransITStudy@nmdp.org
- Keywords: Severe Aplastic Anemia, SAA, Aplastic Anemia, AA, Pediatric, Immunosuppressive Therapy, IST, Unrelated, TransIT, Child, Children, Teen, Adolescent
Note: For the PTCTC NMD2201 / BMT CTN 2202 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via CIBMTR. BMT CTN Centers will receive BMT CTN accrual credits. For questions about the study and how to participate or to access study materials, contact protocol coordinators and TransITStudy@nmdp.org